---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Conclusions"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Conclusions. 1 evidence topic quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary/conclusions"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

COMPASS Pathways completed its NDA for COMP360 in TRD on November 9, 2026, and its Commissioner's National Priority Voucher “could shorten review times to 1-2 months”. Psilocybin is in Schedule I; launch is anticipated in the first half of 2027, subject to FDA approval and DEA rescheduling. TRD affected 2.8 million (30.9%) of 8.9 million US adults with medication-treated MDD and accounted for $43.8 billion in annual burden.

In COMP005 (258 participants), one 25 mg dose reduced MADRS score more than placebo at Week 6 (difference -3.6; p<0.001). In COMP006 (581 participants), two 25 mg doses reduced it more than two 1 mg doses (-3.8; p<0.001). Observed or open-label durability data show an average 13-point reduction at Week 52 in the COMP005 25 mg arm after another dose, and benefit maintained through at least Week 26 by the 39% of the COMP006 25 mg arm with a clinically meaningful Week 6 reduction. Phase 3 results come from company filings, presentations, and congress abstracts. In the peer-reviewed phase 2b COMP001 trial (233 participants), the Week 3 difference for 25 mg versus 1 mg was -6.6 (P<0.001); response and remission at Week 3 were supportive of the primary result, and sustained response at 12 weeks was not.

Headache, nausea, and visual hallucination were common, primarily on dosing days. Serious TEAEs through Week 26 of COMP005 occurred in 4.7% (COMP360) and 2.3% (placebo), and the data safety monitoring board found no clinically meaningful suicidality imbalance in either trial.

Sessions last six to eight hours at a certified treatment center, with two monitoring healthcare providers in the trials and an expected REMS templated on the Spravato REMS.

No price is published. ICER's final evidence report is scheduled for 06/21/2027; published psilocybin analyses report $117,517 per QALY gained or cost savings.

Limitations are functional unblinding, no active comparator, preliminary phase 3 data with no COMP006 registry results, and discrepancies between company sources (40 or 32 COMP005 sites; 581 dosed or 572 enrolled in COMP006).

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm); [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/); [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm); [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/); [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888); [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/); [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/); [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/); [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/); [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm); [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
